1 Embedding of exogenous B cell epitopes on the surface of UreB 2 structure generates a broadly reactive antibody response against 3 *Helicobacter pylori* 4

5 Junfei Ma^a, Shuying Wang^a, Qianyu Ji^a, Jingxuan Qiu^a, Qing Liu^{a,b,1}
6

7 ^a School of Medical Instrument and Food Engineering, University of Shanghai for
8 Science and Technology, Shanghai 200093, China

9 ^b Laboratory for Marine Fisheries Science and Food Production Processes, Qingdao
10 National Laboratory for Marine Science and Technology, Qingdao 266071, China
11

12 **Abstract:** Since *Helicobacter pylori* (*H. pylori*) resistance to antibiotic regimens is
13 increased, vaccination is becoming an increasingly important alternative therapy to
14 control *H. pylori* infection. UreB, FlaA, AlpB, SabA, and HpaA proteins of *H. pylori*
15 were previously proved to be used as candidate vaccine antigens. Here, we developed
16 an engineered antigen based on a recombinant chimeric protein containing a structural
17 scaffold from UreB and B cell epitopes from FlaA, AlpB, SabA, and HpaA. The
18 multi-epitope chimeric antigen, named MECU, could generate a broadly reactive
19 antibody response including antigen-specific antibodies and neutralizing antibodies
20 against *H. pylori* urease and adhesins. Moreover, therapeutic immunization with
21 MECU could reduce *H. pylori* colonization in the stomach and protect the stomach in
22 BALB/c mice. This study not only provides a promising immunotherapy to control *H.*
23 *pylori* infection, but also offers a reference for antigen engineering against other

¹ Corresponding author. School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Tel.: +86 021 65710369 E-mail address: liuq@usst.edu.cn (Q. Liu).

24 pathogens.

25

26 **Keywords:** *Helicobacter pylori*, multi-epitope chimeric antigen, therapeutic
27 immunization, UreB, FlaA, AlpB, SabA, HpaA

28

29 1. Introduction

30 *Helicobacter pylori* (*H. pylori*) infection has been shown to be associated with a
31 series of gastric diseases including chronic gastritis, peptic ulcers, and gastric
32 malignancies^{1,2}. The major antibiotic-based triple regimen has been proven to cause
33 increased antimicrobial resistance³, which results in a reduced eradication rate.
34 Therefore, vaccination could be a more effective and safer immunotherapy to control
35 *H. pylori* infection.

36 The key functional proteins of bacteria, which play an important role in invading
37 and colonizing the host, are generally selected as vaccine antigens. In *H. pylori*,
38 urease could neutralize the stomach acidity and promote chemotaxis by decomposing
39 urea, which is conducive to the bacterial survival^{4,5}. Urease subunit beta (UreB) was
40 widely used as a vaccine antigen against *H. pylori* infection, whose B cell epitopes
41 and CD4⁺ T cell epitopes of UreB had been identified in the previous studies⁶⁻¹¹.
42 Besides, some other proteins of *H. pylori* were also developed as vaccine antigens. A
43 linear B cell epitope of the movement-related protein flagellin A (FlaA) was also
44 identified by experiment¹². *H. pylori* adhesins including sialic acid-binding adhesin
45 (SabA), hop family adhesin AlpB (AlpB), and *H. pylori* adhesin A (HpaA) are known
46 to be promising candidate vaccine antigens against *H. pylori*¹³. Their possible
47 conservative adhesion domains have also been reported in the previous studies¹⁴⁻¹⁶.
48 The immune response induced by above antigens could inhibit the bacterial
49 chemotaxis and adhesion.

50 Since the immune response induced by a single protein antigen is limited, the
51 emphasis on vaccine development has moved to the generation of recombinant
52 multi-epitope vaccines. A multi-epitope vaccine consists of B and T epitopes from

several different antigens in a reasonable order with flexible linkers¹⁷. Compared to the single protein antigen vaccine, the multi-epitope vaccine could activate broadly reactive antibodies, which could lead to an effective immunoreaction blocking multiple pathogenic channels for the pathogen control¹⁸. A variety of multi-epitope vaccines against *H. pylori* could induce high levels of specific antibodies against multiple antigens which are the sources of epitopes¹⁹⁻²¹. The construction of multi-epitope vaccine antigen is undoubtedly the creation and synthesis of a new protein. The rationality of epitope assembly determines the expression certainty, stability, and degradation of the constructed multi-epitope antigen. Proper presentation of antigens, which can efficiently induce the immune system, is strongly dependent on the optimal structural stability of the vaccine construct²². Although computer-aided design could engineer immunogens according to the available structural information, most studies remained at design stage^{23, 24}, suggesting that the string-of-beads structural rationality of multi-epitope vaccine antigen designed by computer aid needs to be proven.

In terms of identifying appropriate engineered antigens to obtain optimal vaccine response, considerable work has focused on structural vaccinology, in which immunogens are rationally engineered using available structural information^{22, 25}. The methods have been developed to transplant epitopes to scaffold proteins for structural stabilization. The engineered immunogens could present one or more key epitopes or immunogenic domains to induce epitope-specific antibodies or generate a broadly reactive antibody response. In recent studies, Roundleaf bat HBV core antigen (RBHBcAg), calcium binding antigen 43 homolog (Cah) and *H. pylori* ferritin were respectively selected as the scaffold proteins for displaying key epitopes or immunogenic domains of pathogens including hepatitis B virus, Shiga toxin-producing *Escherichia coli* and *Borrelia burgdorferi*²⁶⁻²⁸. The structure-based engineered immunogen has higher structural stability and more reasonable epitope exposure compared to epitope-tandem immunogens, which means that it could generate a broader and more persistent antibody response.

In this paper, an engineered immunogen named MECU was designed for displaying

multiple B cell epitopes from FlaA, SabA, AlpB and HpaA on the structural surface of UreB, a scaffold protein which was widely used as *H. pylori* antigen. MECU promotes the production of potent antigen-specific antibodies and neutralizing antibodies against *H. pylori* urease and adhesins. The therapeutic vaccination of MECU showed that it could generate a broadly antibody response and reduce bacterial loads in stomach for controlling *H. pylori* infection in BALB/c mice. The construction of MECU could be a candidate vaccine against *H. pylori* infection and provide a reference for immunogen engineering against other pathogens.

2. Materials and Methods

2.1 Bacteria and animals

The mouse-adapted *H. pylori* strain SS1 was from our lab collection. *H. pylori* was cultured on Columbia agar plates enriched with 7% new-born calf serum, polymyxin B (5 µg/mL), trimethoprim (5 µg/mL), and vancomycin(10 µg/mL) under microaerophilic conditions (5% O₂, 10% CO₂, and 85% N₂) at 37 °C for 3-5 days.

Specific pathogen-free (SPF) BALB/c mice, 5–6 weeks of age, 14±2 g, were purchased from Jiesijie (Shanghai, China). The mice were allowed 1 week to adapt to the environment before starting the experiments. This study was approved by China Ethics Committee.

2.2 Construction and expression of the multi-epitope chimeric antigen

The B cell epitopes in *H. pylori* adhesins (HpaA, AlpB, and SabA) were predicted by BepiPred 2.0 Server²⁹ and a B cell epitope in FlaA were obtained from the Immune Epitope Database (IEDB). The selected epitopes were listed in Table 1. Among them, three epitopes from adhesins contain the previously reported adhesion domains¹⁴⁻¹⁶. Based on the structure of UreB (PDB ID: 1e9zB), five positions (UreB₄₋₁₄, UreB₃₈₋₆₄, UreB₄₆₃₋₄₇₇, UreB₅₁₆₋₅₃₄, UreB₅₅₂₋₅₆₉) in the non-core surface regions at the N-terminal

111 and C-terminal were selected for epitope replacements. After replaced by five B cell
112 epitopes with the available linkers “KK”, “GS”, “GGS”, and “GGGS”, UreB was
113 converted into multi-epitope chimeric UreB (MECU).

114 The amino acid sequence of the constructed MECU was submitted to the
115 I-TASSER Server³⁰ for structure prediction. ProSA-web, RAMPAGE, and Verify 3D
116 sever were used for evaluating the quality of the predicted MECU structure. The
117 Z-score calculated by ProSA-web could assess the overall quality of the predicted
118 structure³¹. The main Ramachandran plot from RAMPAGE was used for calculating
119 phi-psi torsion angles for each amino acid in the vaccine structure³². The Verify 3D
120 Server could score the compatibility of the predicted structure model with the amino
121 acid sequence³³. Besides, the structural alignment of MECU and UreB was performed
122 by TM-align tool³⁴.

123 The amino acid sequence of MECU was submitted to the Jcat tool for Codon
124 optimization, which could achieve maximum expression in *Escherichia coli* (*E. coli*)
125 system³⁵. The optimized DNA sequence was synthesized and cloned into the pET30a
126 plasmid by Sangon Biotech(Shanghai, China). Finally, the recombinant plasmid
127 pET30a-MECU was transformed into *E. coli* BL21(DE3) to express the MECU
128 protein. The MECU protein was purified by affinity chromatography
129 (Ni-IDA-Sefinose Column, Sangon Biotech, China). After that, the purified MECU
130 protein was separated on 12% SDS-PAGE and further probed with mouse polyclonal
131 anti-His (Sigma, USA) and rabbit polyclonal anti-*H. pylori* (GeneTex, USA)
132 antibodies by western blotting with purified UreB as the reference.

133

134 2.3 Subcutaneous immunization with MECU

135 SPF BALB/c mice were randomly divided into 3 groups (n=5), and were
136 vaccinated subcutaneously 3 times at 7-day intervals with 100 µg of the purified
137 MECU, UreB or BSA in complete Freund’s adjuvant (FA, Sigma, USA) on day 0 and
138 in incomplete FA on days 7 and 14. The pure proteins MECU, UreB or BSA were
139 used as immunogens in the last booster immunization on days 21. Serum was

140 collected at 7 days after the last vaccination to determine the specific antibodies.

141 2.4 Determination of specific antibodies after subcutaneous 142 immunization

143 ELISA plates were coated with 1 µg/well of each antigen (UreB, FlaA, SabA, AlpB
144 or HpaA) respectively at 4 °C overnight. After washing, the plates were blocked with 5%
145 (m/V) skim milk for 2 h. The diluted serum samples (1:1000) were added to the
146 antigen-coated plates and incubated for 1 h. After washing, a proper dilution of
147 HRP-conjugated goat anti-mouse IgG (Sigma, USA) was added to the plate and
148 incubated for 1 h. Finally, tetramethylbenzidine (TMB) was added and incubated at
149 room temperature for 15 min. The reaction was then stopped with 2 M H₂SO₄. The
150 absorbance was measured at 450 nm using a microplate reader.

151

152 2.5 Detection of neutralizing antibodies against *H. pylori* urease and 153 adhesins

154 Serum IgG antibodies were purified by protein G column chromatography (GE
155 Healthcare, USA). The purified IgG antibodies were detected by SDS-PAGE. To
156 determine neutralizing antibodies against *H. pylori* urease, *H. pylori* urease (2µg in 50
157 µL, Creative Enzymes, USA) was incubated with purified IgG antibodies (64 µg/well)
158 in 96-well microtiter plates overnight at 4 °C. After that, 100 µL of 50 mM PBS
159 containing 500 mM urea, 0.02% phenol red, and 0.1 mM dithiothreitol (DTT) was
160 added to each well. The absorbance was measured at 550 nm. Percentage inhibition of
161 urease activity = [(activity without antibodies – activity with antibodies)/(activity
162 without antibodies)] × 100 %.

163 To determine the neutralizing antibodies against *H. pylori* adhesins, the AGS
164 human gastric cancer cell adhesion assay was carried out on *H. pylori* SS1 using a
165 CFU counting method. Approximate 2×10⁵ AGS cells were seeded in 12-well plate
166 per well overnight. Approximate 2×10⁷ CFU *H. pylori* cultures were incubated with
167 40 µL of purified IgG antibodies (100 µg/mL) and slightly shaken at room

168 temperature for 2 h. AGS cells were washed three times with PBS, and the *H. pylori*
 169 incubates were added to the wells at a multiplicity of infection of 100. The mixtures
 170 were incubated in a CO₂ incubator at 37 °C for 2 h. After incubation, the wells were
 171 washed 3 times with PBS containing 1% saponin. After the mechanical treatment, the
 172 mixtures were plated onto Columbia agar for bacteria counting. Percentage inhibition
 173 of adhesion = [(CFU without antibodies – CFU with antibodies)/(CFU without
 174 antibodies)] × 100 %.

175

176 2.6 Construction of CTB-MECU for oral immunization

177 To enhance the immunogenicity of oral MECU vaccine, cholera toxin subunit B
 178 (CTB), a widely used mucosal adjuvant, was added to the N-terminus of MECU and
 179 UreB with a flexible linker “DPRVPSS”. After amplification, cloning and
 180 transformation, CTB-MECU and CTB-UreB were also expressed by *E. coli* BL21
 181 (DE3). The proteins were purified by affinity chromatography and assessed by
 182 SDS-PAGE. Their immunoreactivity was evaluated by western blotting.

183 CTB could bind intestinal epithelial cells and antigen presenting cells through
 184 monosialotetrahexosylganglioside (GM1) receptors, which then mediates antigen
 185 entry into the cell³⁶. GM1-ELISA was used to demonstrate the adjuvanticity of CTB
 186 component in CTB-MECU as previously described³⁷. Briefly, ELISA plates were
 187 coated with GM1 ganglioside at 4 °C for 12 h. After washing, ELISA plates were
 188 locked by incubating with 5% (m/V) skim milk for 2 h. The CTB-MECU, CTB-UreB,
 189 CTB, MECU, UreB or BSA proteins were added to the plates and incubated at 37 °C
 190 for 2 h. After washing, a proper dilution (1:1000) of anti-CTB mouse monoclonal
 191 antibody (Sigma, USA) was added to the plates and incubated at 37 °C for 1 h. After
 192 washing, HRP-conjugated goat anti-mouse IgG (Invitrogen, USA) was added to the
 193 plates and incubated at 37 °C for 1 h. Substrate tetramethylbenzidine was then added
 194 and incubated for 15 min. The absorbance was measured at 450 nm.

195 2.7 Infection and therapeutic vaccination

196 SPF BALB/c mice (male, 5-6 weeks old) were infected with *H. pylori* SS1(10⁹

CFU/mouse) intragastrically, four times within the span of two weeks. The *H. pylori*-infected mice were randomly divided into 5 groups (n=5). Considering the different immunization methods, two groups were vaccinated intraperitoneally 3 times at 7-day intervals with 100 µg of the purified MECU or UreB in FA for four times at 1-week intervals. Other two groups were vaccinated intragastrically with 100 µg of antigen (CTB-MECU or CTB-UreB) in 0.2 M sodium hydrogen carbonate buffer (200 µL) for four times at 1-week interval. The last group was vaccinated with both FA in PBS intraperitoneally and CTB intragastrically as a control. Two weeks after the final immunization, the mice were sacrificed and examined. The whole therapeutic vaccination procedure was showed in Fig. 6A.

2.8 Assay of specific IgG in serum and SIgA in stomach mucosa

ELISA plates were coated with 5µg/mL *H. pylori* lysates at 4 °C overnight. To determine specific IgG, the antisera were collected and diluted 1:1,000 in PBS. To determine secretory IgA (SIgA), one-fourth of stomach tissue was homogenized in 1 mL of PBS containing 0.1 mM Phenylmethanesulfonyl fluoride (PMSF). The supernatant was collected and diluted 1:5 in PBS. An HRP-conjugated goat anti-mouse IgG or an HRP-conjugated goat anti-mouse IgA (Sigma, USA) was used as the secondary antibody.

2.9 Examination of *H. pylori* colonization in stomachs

To examine the *H. pylori* colonization in stomachs, one-fourth of stomach tissue was weighed and homogenized in 1 mL of PBS. Serial 10-fold dilutions of the stomach homogenate were plated on Columbia agar supplemented with 7 % new-born calf serum and *H. pylori* selective supplement (Oxoid, UK). After cultured for 4-6 days at 37 °C, colonies were counted and the number of CFU per stomach was calculated.

2.10 Gastric histology

226 One fragment of stomach tissue was fixed with formalin, embedded in paraffin and
227 stained with hematoxylin and eosin (HE) according to the standard procedure³⁸.

228

229 2.11 Cytokine production

230 To determine cytokine production, the splenic lymphocytes were isolated and
231 cultured (2×10^5 cells/well) with *H. pylori* lysates (5 μ g/mL) in 12-well plates at 37 °C
232 for 72 h. The culture supernatants were collected for the determination of IFN- γ , IL-4,
233 and IL-17 using ELISA kits (Jiang Lai Biotech, Shanghai, China) according to the
234 manufacturer's instructions.

235

236 2.12 Statistical analyses

237 All independent experiments carried out in this study and showed in figures were
238 biological replicates. All data were analyzed with GraphPad Prism software using
239 One-way ANOVA. $P < 0.05$ was considered as statistically significant (* $p < 0.05$, **
240 $p < 0.01$, *** $p < 0.001$; ns, not significant).

241

242 3. Results

243 3.1 Construction and expression of MECU antigen

244 Based on the structural framework of UreB, five B cell epitopes from four antigens
245 associated with adhesion or motion (HpaA, AlpB, SabA, and FlaA) were chosen to
246 construct the MECU antigen (Fig. 1A). On the one hand, the epitopes located in the
247 non-core regions next to the N-terminal and C-terminal of MECU primary structure.
248 On the other hand, the insertion of exogenous epitopes did not affect the integrity of
249 UreB own epitopes (Fig. 1B). This made the antigenicity of UreB fully embodied in
250 MECU.

251 Subsequently, the 3D structure of MECU was predicted by I-TASSER Server, a
252 modeling structure prediction tool (Fig. 2A). In order to evaluate the structural
253 reliability of the predicted structure, ProSA-web, RAMPAGE, and Verify 3D servers

254 were used. The Z-score of MECU structure calculated by ProSA-web was -7.12,
255 which is in the range of native protein conformation scores (Fig. 2B). Ramachandran
256 plot from RAMPAGE showed that 92.5 % of residues were in favored region; 6.0 %
257 of residues were in allowed region and 1.5 % of residues in outlier region (Fig. 2C).
258 Verify 3D results showed that 86.83% of the residues have averaged 3D-1D score =
259 0.2 (Fig. 2D). All these results indicated that the predicted structure of MECU was
260 reasonable and reliable.

261 Further, the structural alignment of MECU and UreB was performed by TM-align,
262 which indicated that the structure of MECU was highly similar to that of UreB
263 (RMSD = 0.62, Fig. 3A). The secondary structures of exogenous epitopes and
264 replaced regions of UreB were analyzed for evaluating the design rationality. Both the
265 B cell epitopes and replaced peptides contained the flexible loop fragment, whose
266 substitutions at UreB-terminal had little effect on the stability of the whole skeleton
267 (Fig. 3B). It could be seen that the chimeric epitopes were displayed on the surface of
268 the MECU structure, which was beneficial to antibody binding (Fig. 3C).

269 The MECU protein was successfully expressed and purified, whose molecular
270 weight was similar to that of UreB (Fig. 3D). Both MECU and UreB protein could be
271 recognized by mouse anti-His polyclonal antibody and rabbit anti-*H. pylori*
272 polyclonal antibody (Fig. 3E).

273

274 3.2 Broadly reactive antibodies generated by MECU immunogen

275 To evaluate the actual effect of MECU design initially, mice were subcutaneously
276 immunized by MECU for assay of antigen-specific antibodies in antisera. MECU
277 could induce high levels of multiple antibodies specific to *H. pylori* antigens (UreB,
278 FlaA, AlpB, SabA, and HpaA) while UreB could only induce high levels of antibodies
279 to itself (Fig. 4A). It indicated that the epitopes from FlaA, AlpB, SabA, and HpaA
280 have good immunogenicity and immunoreactivity, and MECU is a multivalent
281 vaccine. In addition, the insertion of exogenous epitopes didn't affect the humoral
282 immunity of UreB in MECU due to the similar levels of antibodies specific to UreB.

283 To assay the neutralizing antibodies against *H. pylori* urease and adhesins, mouse
284 IgG in antisera was purified and identified by SDS-PAGE (Fig. 4B). Anti-MECU IgG
285 or anti-UreB IgG could inhibit the enzyme activity of *H. pylori* urease. However, the
286 IgG induced by BSA had no significant inhibition (Fig. 4C). Besides, anti-MECU IgG
287 or anti-UreB IgG could inhibit *H. pylori* adhesin to AGS cells, while anti-BSA IgG
288 had no significant inhibition (Fig. 4D). Importantly, anti-MECU IgG had better
289 adhesion inhibition to AGS cells than anti-UreB IgG.

290

291 3.3 Construction of CTB-MECU for oral immunization

292 According to the schematic representation (Fig. 5A), CTB-MECU immunogen was
293 constructed by the addition of CTB to N-terminal of MECU with a flexible linker
294 “DPRVPSS” and the construction of CTB-UreB was used as a reference. The
295 CTB-MECU and CTB-UreB proteins were successfully expressed and purified (Fig.
296 5B). They could be identified by mouse anti-His polyclonal antibody and rabbit
297 anti-*H. pylori* polyclonal antibody (Fig. 5C). Furthermore, the adjuvanticity of CTB in
298 CTB-MECU was analyzed by GM1-ELISA. CTB-MECU and CTB-UreB were both
299 able to bind the coating GM1, even though their binding abilities were weaker than
300 the positive control CTB (Fig. 5D). UreB, MECU or the negative control BSA could
301 not bind GM1 without the addition of CTB.

302

303 3.4 Evaluation of therapeutic vaccination

304 To evaluate the therapeutic effect of the constructed vaccine, MECU and UreB
305 were vaccinated with FA intraperitoneally or with CTB intragastrically according to
306 the procedure of therapeutic vaccination (Fig. 6A). The specific IgG and SIgA
307 antibodies against *H. pylori* lysates were analyzed by ELISA after therapeutic
308 vaccination. The measurement of *H. pylori* lysates-specific IgG antibodies in serum
309 showed that mice immunized with MECU or UreB by intraperitoneal or oral route
310 elicited significantly higher levels of IgG than the control (CTB+PBS+FA) group (Fig.
311 6B). In general, intraperitoneal vaccination induced higher levels of specific IgG

antibodies than the oral route, which was significant in both UreB and MECU group. In addition, intraperitoneal vaccination with MECU induced higher levels of specific IgG antibodies than that with UreB, which was no difference in oral immunization. Oral immunization with MECU or UreB plus CTB remarkably increased the levels of SIgA antibodies against *H. pylori* lysates compared to the control group (Fig 6C). Moreover, CTB-MECU induced higher levels of SIgA antibodies against *H. pylori* lysates than CTB-UreB. Intraperitoneal vaccination with MECU or UreB did not induce significant SIgA antibodies against *H. pylori* lysates compared to the control group.

The *H. pylori* colonization in the stomach was analyzed by quantitative culture. Compared with the control group, both two immunization routes with UreB or MECU significantly decreased the *H. pylori* loads in the stomachs (Fig 6D). Oral immunization had a better reduction of bacterial burden than intraperitoneal immunization, which was significant in MECU groups. Besides, MECU vaccination performed better at reducing bacterial colonization than UreB vaccination in oral immunization routes.

Further, the relevant cytokines IFN- γ , IL-4, and IL-17 in the supernatants of splenic lymphocyte cultures were determined after stimulation with *H. pylori* lysates using ELISA. *H. pylori* lysates significantly induced high levels of IFN- γ (Fig. 6E), IL-4 (Fig. 6F), and IL-17 (Fig. 6G) in splenic lymphocytes from mice immunized with UreB or MECU in both two immunization routes, but not those from the control group. There were no significant differences at the levels of IFN- γ , IL-4, and IL-17 cytokines between UreB and MECU group in each immunization route. However, the levels of IFN- γ , IL-4, and IL-17 in splenic lymphocytes from mice with intraperitoneal vaccination were higher than those with oral vaccination.

Therapeutic effect of MECU was also analyzed by histopathological analysis of stomach tissue. A severe stomach ulcer was found in the stomach from mice immunized with CTB and PBS plus FA. Erosive gastric epithelium was found in the stomach from mice immunized with UreB plus FA. Moderate or mild levels of inflammatory cell infiltration were found in the stomach immunized with UreB plus

342 FA, MECU plus FA, CTB-UreB, or CTB-MECU (Fig. 6H).

343

344 4. Discussion

345 Urease, a key functional protein that helps *H. pylori* to colonize in the stomach, has
 346 become an important target for immunotherapy. The strongly immunogenic subunit
 347 UreB is a widely used antigen in the *H. pylori* vaccine studies³⁹. However, the
 348 immune response induced by a single antigen is still limited. In this study, we
 349 constructed a multi-epitope chimeric antigen based on UreB structure, named MECU.
 350 Five positions on the surface of UreB structure were selected for displaying the
 351 exogenous B cell epitopes from FlaA, AlpB, SabA and HpaA. The replacement sites
 352 of exogenous epitopes did not affect inherent B or T cell epitopes of UreB, which
 353 means that UreB is not only a scaffold protein, but also retains its original strong
 354 immunogenicity (Fig. 1).

355 To further evaluate the design rationality of MECU, the constructed sequence was
 356 submitted to I-TASSER server for structural prediction. The structural alignment of
 357 UreB and MECU showed that the replacement of exogenous epitopes did not
 358 significantly change the principal skeleton of UreB structure (RMSD = 0.62). The
 359 exogenous epitopes could be displayed on the surface of MECU, which means that
 360 they have apparent accessibility to generate the humoral immune responses. Both the
 361 replaced peptides and the inserted B cell epitopes mostly contain flexible loop
 362 structures, which could ensure the stability of MECU structure to some extent.

363 After subcutaneous immunization, MECU induced a broader antibody response
 364 against antigens including FlaA, AlpB, SabA, and HpaA compared to UreB (Fig. 4A).
 365 In addition, the level of anti-*H. pylori* antibody in the antiserum from mice
 366 immunized with MECU was increased compared to that with UreB. Similar trends
 367 could be observed at the levels of anti-*H. pylori* IgG from mice with intraperitoneal
 368 immunization (Fig. 6B) and anti-*H. pylori* SIgA from mice with oral immunization
 369 (Fig. 6C). Besides, the purified anti-MECU antibodies could significantly inhibit the
 370 adhesion of *H. pylori* to AGS cells compared to anti-UreB antibodies (Fig. 4D). These

371 results indicated that the exogenous B cell epitopes in MECU achieved the desired
372 effect.

373 On the one hand, after immunogen engineering, MECU still induced a similar level
374 of anti-UreB antibody to UreB (Fig. 4A). So did the anti-*H. pylori* urease neutralizing
375 antibodies (Fig. 4C). On the other hand, there were no significant differences at the
376 levels of IFN- γ , IL-4, and IL-17 cytokines between UreB and MECU group in both
377 two immunization routes (Fig. 6E-G). This indicated that the inherent B and T cell
378 epitopes of UreB were not affected by the replacements of exogenous epitopes. The
379 original immunogenicity of UreB remained in MECU.

380 Both intraperitoneal vaccination and oral vaccination could significantly reduce the
381 *H. pylori* colonization in the stomach and oral vaccination is more effective (Fig 6D).
382 It results from that mucosal immunity could induce high levels of *H. pylori*-specific
383 SIgA, the most abundant immunoglobulin of the mammalian mucosa (Fig 6C). In fact,
384 the ability to induce significant levels of SIgA is a priority for the development of
385 vaccine immunogens against gastrointestinal pathogens. The vaccines against *H.*
386 *pylori* were mostly vaccinated intragastrically or nasally to induce mucosal immunity
387 and produce high levels of specific SIgA⁴⁰. In addition, CTB, a safe and efficient
388 mucosal adjuvant, could enhance the levels of mucosal immunity⁴¹. However,
389 intraperitoneal vaccination without inducing significant levels of *H. pylori*-specific
390 SIgA could also reduce *H. pylori* colonization in the stomach, which was less
391 effective than oral vaccination (Fig. 6C,D). It is possible to correlate the protection
392 achieved with high levels of *H. pylori*-specific IgG (Fig. 6B). Some studies revealed
393 that IgG in the murine intestine leads to the elimination of the Shiga toxin-producing
394 *Escherichia coli*, virulent *Citrobacter rodentium*, and rotavirus^{27, 42, 43}. The vaccines
395 against *H. pylori* were also vaccinated by systemic immune routes such as
396 intramuscular immunization^{44, 45}. Consequently, our results and those reported by
397 others support the idea that the effector functions of IgG in the defense against
398 gastrointestinal pathogens shouldn't be ignored.

399 In conclusion, we developed a promising formulation based on a recombinant
400 chimeric protein named MECU, which was produced by the embedding of exogenous

401 B cell epitopes on the surface of UreB structure. It could generate a broadly reactive
402 antibody response and reduce *H. pylori* colonization in the murine stomach. Our study
403 supports that the recombinant chimera containing epitopes of different antigens of *H.*
404 *pylori* has the prospect of becoming an effective immunotherapy to control *H. pylori*
405 infection.

406

407 Acknowledgement

408 **Funding:** This work was supported by the National Natural Science
409 Foundation of China [31871897] and Science and Technology innovation
410 Plan of Shanghai [19391902000].

411

412 Conflict of interest

413 Declarations of interest: none.

414

415

416 References

417

- 418 1. Rokkas, T.; Gisbert, J. P.; Niv, Y.; O'Morain, C., The association between *Helicobacter*
419 *pylori* infection and inflammatory bowel disease based on meta-analysis. *United European*
420 *Gastroenterology Journal* **2015**, *3* (6), 539-550.
- 421 2. Lee, Y.-C.; Chiang, T.-H.; Chou, C.-K.; Tu, Y.-K.; Liao, W.-C.; Wu, M.-S.; Graham,
422 D. Y., Association Between *Helicobacter pylori* Eradication and Gastric Cancer Incidence: A
423 Systematic Review and Meta-analysis. *Gastroenterology* **2016**, *150* (5), 1113-+.
- 424 3. Suzuki, S.; Esaki, M.; Kusano, C.; Ikehara, H.; Gotoda, T., Development of
425 *Helicobacter pylori* treatment: How do we manage antimicrobial resistance? *World J.*

426 *Gastroenterol.* **2019**, *25*(16), 1907-1912.

427 4. Hatakeyama, M.; Brzozowski, T., Pathogenesis of *Helicobacter pylori* infection.

428 *Helicobacter* **2006**, *11*, 14-20.

429 5. Huang, J. Y.; Sweeney, E. G.; Sigal, M.; Zhang, H. C.; Remington, S. J.; Cantrell,

430 M. A.; Kuo, C. J.; Guillemin, K.; Amieva, M. R., Chemodetection and Destruction of Host

431 Urea Allows *Helicobacter pylori* to Locate the Epithelium. *Cell Host & Microbe* **2015**, *18* (2),

432 147-156.

433 6. Hirota, K.; Nagata, K.; Norose, Y.; Futagami, S.; Nakagawa, Y.; Senpuku, H.;

434 Kobayashi, M.; Takahashi, H., Identification of an antigenic epitope in *Helicobacter pylori*

435 urease that induces neutralizing antibody production. *Infection and Immunity* **2001**, *69* (11),

436 6597-6603.

437 7. Li, H.-X.; Mao, X.-H.; Shi, Y.; Ma, Y.; Wu, Y.-N.; Zhang, W.-J.; Luo, P.; Yu, S.;

438 Zhou, W.-Y.; Guo, Y.; Wu, C.; Guo, G.; Zou, Q.-M., Screening and identification of a

439 novel B-cell neutralizing epitope from *Helicobacter pylori* UreB. *Vaccine* **2008**, *26* (52),

440 6945-6949.

441 8. Qiu, Y.; Wang, Y.-C.; Tao, H.-X.; Zhan, D.-W.; Yuan, S.-L.; Wang, P.; Wang,

442 L.-C.; Han, X.-P.; Li, C.-S.; Li, J.-K.; Liu, C.-J., Identification of B-cell epitopes in urease B

443 subunit of *Helicobacter pylori* bound by neutralizing antibodies. *Vaccine* **2010**, *28* (32),

444 5220-5227.

445 9. Shi, Y.; Wu, C.; Zhou, W.-Y.; Mao, X.-H.; Guo, G.; Zou, Q.-M., Identification of

446 H-2(d) restricted Th epitopes in Urease B subunit of *Helicobacter pylori*. *Vaccine* **2007**, *25*(14),

447 2583-2590.

- 448 10. Yang, W.-C.; Chen, L.; Li, H.-B.; Li, B.; Hu, J.; Zhang, J.-Y.; Yang, S.-M.; Zou,
449 Q.-M.; Guo, H.; Wu, C., Identification of two novel immunodominant UreB CD4(+) T cell
450 epitopes in Helicobacter pylori infected subjects. *Vaccine* **2013**, *31*(8), 1204-1209.
- 451 11. Li, B.; Chen, L.; Sun, H.; Yang, W.; Hu, J.; He, Y.; Wei, S.; Zhao, Z.; Zhang,
452 J.; Li, H.; Zou, Q.; Wu, C., Immunodominant epitope-specific Th1 but not Th17 responses
453 mediate protection against Helicobacter pylori infection following UreB vaccination of BALB/c
454 mice. *Scientific Reports* **2015**, *5*.
- 455 12. Ji, W.-S.; Hu, J.-L.; Wu, K.-C.; Qiu, J.-W.; Han, Z.-Y.; Ding, J.; Fan, D.-M.,
456 Helicobacter pylori specific immune response induced by conservative flagellin linear B-cell
457 epitope. *World J. Gastroenterol.* **2005**, *11*(23), 3528-3532.
- 458 13. Banga Ndzouboukou, J.-L.; Lei, Q.; Ullah, N.; Zhang, Y.; Hao, L.; Fan, X.,
459 Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
460 *Helicobacter* **2020**, e12758-e12758.
- 461 14. Pang, S. S.; Stanley Thai Son, N.; Perry, A. J.; Day, C. J.; Panjikar, S.; Tiralongo,
462 J.; Whisstock, J. C.; Kwok, T., The Three-dimensional Structure of the Extracellular
463 Adhesion Domain of the Sialic Acid-binding Adhesin SabA from Helicobacter pylori. *Journal of*
464 *Biological Chemistry* **2014**, *289*(10), 6332-6340.
- 465 15. Yonezawa, H.; Osaki, T.; Fukutomi, T.; Hanawa, T.; Kurata, S.; Zaman, C.;
466 Hojo, F.; Kamiya, S., Diversification of the AlpB Outer Membrane Protein of Helicobacter pylori
467 Affects Biofilm Formation and Cellular Adhesion. *Journal of Bacteriology* **2017**, *199*(6).
- 468 16. Evans, D. G.; Karjalainen, T. K.; Evans, D. J., Jr.; Graham, D. Y.; Lee, C. H., Cloning,
469 nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of

- 470 *Helicobacter pylori*. *Journal of bacteriology* **1993**, *175*(3), 674-83.
- 471 17. Nezafat, N.; Eslami, M.; Negahdaripour, M.; Rahbar, M. R.; Ghasemi, Y., Designing
- 472 an efficient multi-epitope oral vaccine against *Helicobacter pylori* using immunoinformatics and
- 473 structural vaccinology approaches. *Molecular Biosystems* **2017**, *13*(4), 699-713.
- 474 18. Meza, B.; Ascencio, F.; Sierra-Beltran, A. P.; Torres, J.; Angulo, C., A novel design
- 475 of amulti-antigenic, multistage and multi-epitope vaccine against *Helicobacter pylori*: An in
- 476 silico approach. *Infection Genetics and Evolution* **2017**, *49*, 309-317.
- 477 19. Guo, L.; Yang, H.; Tang, F.; Yin, R.; Liu, H.; Gong, X.; Wei, J.; Zhang, Y.; Xu,
- 478 G.; Liu, K., Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP,
- 479 Urease, HSP60, and HpaA, Provides Therapeutic Effect on *H. pylori* Infection in Mongolian
- 480 gerbils. *Frontiers in Cellular and Infection Microbiology* **2017**, *7*.
- 481 20. Guo, L.; Yin, R.; Xu, G.; Gong, X.; Chang, Z.; Hong, D.; Liu, H.; Ding, S.;
- 482 Han, X.; Li, Y.; Tang, F.; Liu, K., Immunologic properties and therapeutic efficacy of a
- 483 multivalent epitope-based vaccine against four *Helicobacter pylori* adhesins (urease, Lpp20,
- 484 HpaA, and CagL) in Mongolian gerbils. *Helicobacter* **2017**, *22*(6).
- 485 21. Pan, X.; Ke, H.; Niu, X.; Li, S.; Lv, J.; Pan, L., Protection against *Helicobacter pylori*
- 486 Infection in BALB/c Mouse Model by Oral Administration of Multivalent Epitope-Based Vaccine
- 487 of Cholera Toxin B Subunit-HUUC. *Frontiers in Immunology* **2018**, *9*.
- 488 22. Kulp, D. W.; Schief, W. R., Advances in structure-based vaccine design. *Current Opinion*
- 489 *in Virology* **2013**, *3*(3), 322-331.
- 490 23. Negahdaripour, M.; Nezafat, N.; Eslami, M.; Ghoshoon, M. B.; Shoolian, E.;
- 491 Najafipour, S.; Morowvat, M. H.; Dehshahri, A.; Erfani, N.; Ghasemi, Y., Structural

492 vaccinology considerations for in silico designing of a multi-epitope vaccine. *Infection Genetics*
493 *and Evolution* **2018**, *58*, 96-109.

494 24. Rahman, N.; Ajmal, A.; Ali, F.; Rastrelli, L., Core proteome mediated therapeutic target
495 mining and multi-epitope vaccine design for *Helicobacter pylori*. *Genomics* **2020**, *112* (5),
496 3473-3483.

497 25. Kanekiyo, M.; Ellis, D.; King, N. P., New Vaccine Design and Delivery Technologies.
498 *Journal of Infectious Diseases* **2019**, *219*, S88-S96.

499 26. Zhang, T.-Y.; Guo, X.-R.; Wu, Y.-T.; Kang, X.-Z.; Zheng, Q.-B.; Qi, R.-Y.; Chen,
500 B.-B.; Lan, Y.; Wei, M.; Wang, S.-J.; Xiong, H.-L.; Cao, J.-L.; Zhang, B.-H.; Qiao,
501 X.-Y.; Huang, X.-F.; Wang, Y.-B.; Fang, M.-J.; Zhang, Y.-L.; Cheng, T.; Chen, Y.-X.;
502 Zhao, Q.-J.; Li, S.-W.; Ge, S.-X.; Chen, P.-J.; Zhang, J.; Yuan, Q.; Xia, N.-s., A unique
503 B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface
504 antigen in mice. *Gut* **2020**, *69* (2), 343-354.

505 27. Montero, D. A.; Del Canto, F.; Salazar, J. C.; Cespedes, S.; Cadiz, L.;
506 Arenas-Salinas, M.; Reyes, J.; Onate, A.; Vidal, R. M., Immunization of mice with chimeric
507 antigens displaying selected epitopes confers protection against intestinal colonization and
508 renal damage caused by Shiga toxin-producing *Escherichia coli*. *Npj Vaccines* **2020**, *5* (1).

509 28. Kamp, H. D.; Swanson, K. A.; Wei, R. R.; Dhal, P. K.; Dharanipragada, R.; Kern,
510 A.; Sharma, B.; Sima, R.; Hajdusek, O.; Hu, L. T.; Wei, C.-J.; Nabel, G. J., Design of a
511 broadly reactive Lyme disease vaccine. *Npj Vaccines* **2020**, *5* (1).

512 29. Jespersen, M. C.; Peters, B.; Nielsen, M.; Marcatili, P., BepiPred-2.0: improving
513 sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic Acids*

514 *Research* **2017**, *45*(W1), W24-W29.

515 30. Roy, A.; Kucukural, A.; Zhang, Y., I-TASSER: a unified platform for automated protein
516 structure and function prediction. *Nature Protocols* **2010**, *5*(4), 725-738.

517 31. Wiederstein, M.; Sippl, M. J., ProSA-web: interactive web service for the recognition of
518 errors in three-dimensional structures of proteins. *Nucleic Acids Research* **2007**, *35*,
519 W407-W410.

520 32. Lovell, S. C.; Davis, I. W.; Adrendall, W. B.; de Bakker, P. I. W.; Word, J. M.;
521 Prisant, M. G.; Richardson, J. S.; Richardson, D. C., Structure validation by C alpha
522 geometry: phi,psi and C beta deviation. *Proteins-Structure Function and Genetics* **2003**, *50*(3),
523 437-450.

524 33. Eisenberg, D.; Luthy, R.; Bowie, J. U., VERIFY3D: assessment of protein models with
525 three-dimensional profiles. *Methods in enzymology* **1997**, *277*, 396-404.

526 34. Zhang, Y.; Skolnick, J., TM-align: a protein structure alignment algorithm based on the
527 TM-score. *Nucleic Acids Research* **2005**, *33*(7), 2302-2309.

528 35. Grote, A.; Hiller, K.; Scheer, M.; Munch, R.; Nortemann, B.; Hempel, D. C.; Jahn,
529 D., JCat: a novel tool to adapt codon usage of a target gene to its potential expression host.
530 *Nucleic Acids Research* **2005**, *33*, W526-W531.

531 36. Baldauf, K. J.; Royal, J. M.; Hamorsky, K. T.; Matoba, N., Cholera Toxin B: One
532 Subunit with Many Pharmaceutical Applications. *Toxins* **2015**, *7*(3), 974-996.

533 37. Areas, A. P. M.; Oliveira, M. L. S.; Miyaji, E. N.; Leite, L. C. C.; Aires, K. A.; Dias,
534 W. O.; Ho, P. L., Expression and characterization of cholera toxin B - pneumococcal surface
535 adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune

536 response in mice. *Biochemical and Biophysical Research Communications* **2004**, *321* (1),
537 192-196.

538 38. Feldman, A. T.; Wolfe, D., Tissue processing and hematoxylin and eosin staining.
539 *Methods in molecular biology (Clifton, N.J.)* **2014**, *1180*, 31-43.

540 39. Mirzaei, N.; Poursina, F.; Moghim, S.; Rashidi, N.; Safaei, H. G., The study of
541 H-pylori putative candidate factors for single- and multi-component vaccine development.
542 *Critical Reviews in Microbiology* **2017**, *43*(5), 631-650.

543 40. Blanchard, T. G.; Czinn, S. J., Current Status and Prospects for a Helicobacter pylori
544 Vaccine. *Gastroenterology Clinics of North America* **2015**, *44*(3), 677-+.

545 41. Royal, J. M.; Matoba, N., Therapeutic Potential of Cholera Toxin B Subunit for the
546 Treatment of Inflammatory Diseases of the Mucosa. *Toxins* **2017**, *9*(12).

547 42. Kamada, N.; Sakamoto, K.; Seo, S.-U.; Zeng, M. Y.; Kim, Y.-G.; Cascalho, M.;
548 Vallance, B. A.; Puente, J. L.; Nunez, G., Humoral Immunity in the Gut Selectively Targets
549 Phenotypically Virulent Attaching-and-Effacing Bacteria for Intraluminal Elimination. *Cell Host*
550 *& Microbe* **2015**, *17*(5), 617-627.

551 43. Westerman, L. E.; McClure, H. M.; Jiang, B. M.; Almond, J. W.; Glass, R. I., Serum
552 IgG mediates mucosal immunity against rotavirus infection. *Proc. Natl. Acad. Sci. U. S. A.*
553 **2005**, *102*(20), 7268-7273.

554 44. Malfetheriner, P.; Selgrad, M.; Wex, T.; Romi, B.; Borgogni, E.; Spensieri, F.;
555 Zedda, L.; Ruggiero, P.; Pancotto, L.; Censini, S.; Palla, E.; Kanesa-Thanan, N.;
556 Scharschmidt, B.; Rappuoli, R.; Graham, D. Y.; Schiavetti, F.; Del Giudice, G., Efficacy,
557 immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy

558 volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2

559 study. *Lancet Gastroenterology & Hepatology* **2018**, 3(10), 698-707.

560 45. Malfertheiner, P.; Schultze, V.; Rosenkranz, B.; Kaufmann, S. H. E.; Ulrichs, T.;

561 Novicki, D.; Norelli, F.; Contorni, M.; Peppoloni, S.; Berti, D.; Tornese, D.; Ganju, J.;

562 Palla, E.; Rappuoli, R.; Scharschmidt, B. F.; Del Giudice, G., Safety and immunogenicity of

563 an intramuscular *Helicobacter pylori* vaccine in noninfected volunteers: A Phase I study.

564 *Gastroenterology* **2008**, 135(3), 787-795.

565

Fig. 1 (A) Schematic representation of MECU construction. (B) The sequence of constructed MECU. Five peptide sequences in UreB were replaced by epitopes of HpaA, AlpB, SabA, and FlaA with linkers “KK”, “GS”, and “GGS”. The inherent B cell epitope sequences of UreB were marked by red dotted box and the inherent T cell epitope sequences of UreB were marked by blue dotted box. Besides, the epitope sequences from multiple antigens were marked by different colors.

Fig. 2 Tertiary structure prediction and validation of vaccine protein MECU. (A) Tertiary structure of MECU predicted by I-TASSER. (B) The z-score plot of the predicted structure by ProSA-web. Z-score= -7.12. (C) Ramachandran plot analysis of the predicted structure. Number of residues in favored region: 92.5 %; Number of residues in allowed region: 6.0 %; Number of residues in outlier region: 1.5%. (D) Verify3D analysis of the predicted structure. 86.83% of the residues have averaged 3D-1D score = 0.2.

Fig. 3 The design strategy and production of MECU. (A) Structural alignment of MECU (Red) and UreB (Green). RMSD=0.62. (B) The secondary structural changes of chimeric epitopes from the original antigens to MECU. (C) Epitope map of MECU. (D) Expression and purification of MECU visualized by SDS-PAGE. M: Marker; 1, UreB; 2, MECU. (E) Identity verification of MECU using Western blotting. M: Marker; 1, UreB; 2, MECU.

Fig. 4. Evaluation of antibody response generated by MECU. (A) Determination of antigen-specific antibody in serum by ELISA after subcutaneous immunization with MECU, UreB, or BSA. (B) Visualization of IgG purified from serum of mice immunized by MECU, UreB, or BSA. M, Marker; 1, BSA; 2, UreB; 3, MECU (C) *H. pylori* urease neutralization test of the purified IgG. (D) Adherence inhibition assay of the purified IgG. These results were verified in triplicate assays. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$, ns, not significant.

Fig. 5 Construction of CTB-MECU for oral immunization. (A) Schematic representation of CTB-MECU construction with CTB-UreB as a reference. (B) Expression and purification of CTB-MECU visualized by SDS-PAGE. M, Marker; 1, UreB; 2, CTB-UreB; 3, MECU; 4, CTB-MECU. (C) Immunoreactivity of CTB-MECU probed by mouse anti-His polyclonal antibody and rabbit anti-*H. pylori* polyclonal antibody. M, Marker; 1, UreB; 2, CTB-UreB; 3, MECU; 4, CTB-MECU. (D) The adjuvant effect of CTB in CTB-MECU by GM1-ELISA. These results were verified in triplicate assays. ***p < 0.001, ns, not significant.

Fig. 6 Evaluation of therapeutic vaccination. (A) The procedure of infection and therapeutic vaccination. Determination of serum IgG (B) or stomach SIgA (C) against *H. pylori* lysates after therapeutic vaccination (n=5). (D) Quantification of gastric *H. pylori* colonization by CFU counting. IFN- γ (E), IL-4 (F), and IL-17 (G) production in splenic lymphocytes stimulated by *H. pylori* lysates after therapeutic vaccination. (H) Gastric histology after oral therapeutic vaccination (HE stain). 1, Gastric ulcer; 2, Mucosal epithelial cells exfoliate and become necrotic, forming erosion; 3, Hemangiectasis; 4, Inflammatory cell infiltration. ***p < 0.001, **p < 0.01, *p < 0.05, ns, not significant.

Table 1 The selected B cell epitopes from HpaA, AlpB, SabA, and FlaA.

Epitope	Length	Position in MECU	Sequence	Source	Reference
HpaA ₁₃₁₋₁₄₂	12	4-14	PDPKRTIQKKSE*	BepiPred	16
AlpB ₁₀₆₋₁₃₂	27	38-64	SITQCGATNSGSSGGATAAATTSSTGS*	BepiPred	15
SabA ₁₈₁₋₁₉₁	11	463-477	ATDSTSNPPNS	BepiPred	\
SabA ₁₄₈₋₁₆₁	14	516-534	TYDKMKKLAEDLQA*	BepiPred	14
FlaA ₂₆₇₋₂₇₉	13	552-569	KNDS DGRLVAAIN	IEDB	12

* Contains adhesion domain.